Extended Data Fig. 1: Clinical timelines, toxicity profiles and interventions in patients treated with ESO-T01.

a, Timelines illustrating infusion, CRS onset and duration, ICANS, administration of corticosteroids or tocilizumab, and the time of peak CAR-T expansion (Cmax). b, Maximum CRS and ICANS grades according to ASTCT criteria, together with the duration of CRS (days) in each patient. c, Summary of adverse events in the cohort, including infections, elevated AST/ALT and electrolyte abnormalities. Heatmap intensity indicates the maximum recorded grade for each event. Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cmax, maximum CAR-T cell concentration; CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome.